Optimized ribosomal profiling technologies, under Eclipsebio’s eRibo™ product family, are now commercially available for faster and easier acquisition of ribosomal occupancy data to study protein translation
SAN DIEGO, January 31, 2023 – Eclipse Bioinnovations (Eclipsebio), a leading RNA genomics company developing and commercializing novel, data-driven technologies that interrogate RNA, today announced the launch of its eRibo™ suite of technologies, providing methods that improve upon differential expression analysis compared to the traditional Ribo-Seq. Details on how eRibo works and its capabilities will be shared in a poster presentation and a workshop at the Keystone Symposia on Molecular & Cellular Biology: Protein RNA Interactions Meeting, taking place from January 29 to February 1 in Vancouver, British Columbia.
“We are excited to announce that our customers can now benefit from our eRibo technology to improve their research on protein translation,” said Eclipsebio CEO and cofounder Peter Chu, Ph.D. “Scientists interested in determining changes in protein translation will benefit from using this method and will be able to explore ribosome profiling in a faster, easier way than when using traditional Ribo-Seq technologies or shotgun proteomics.”
The eRibo product family consists of:
-
- eRibo 3’ that delivers a rapid, easy, and efficient approach to count ribosome-associated polyadenylated transcripts and gene-level ribosome occupancy
- eRibo Total that allows the study of transcriptome-wide ribosome occupancy while enabling the interrogation of splicing events
Presentation Information:
- Poster Session 2: Tuesday, January 31, 7:30 PM PST
Maya Kunkel, Ph.D., Principal Scientist at Eclipsebio
eRibo: A Simplified and Robust Method for Profiling Protein Translation
Poster #2021 - Workshop 2 (J8): Wednesday, February 1, 2:30 PM PST
Eric Van Nostrand, Ph.D., co-founder of Eclipsebio and assistant professor at Baylor College of Medicine, Houston
Characterizing RNA Binding Protein-Mediated Regulation of Transcription with ribo-eCLIP
About Eclipsebio’s RNA Genomics Platform and Products
Eclipsebio’s comprehensive RNA genomics platform is poised to build the world’s most detailed multi-dimensional RNA maps through transcriptome-wide views of RNA interactions with RNA binding proteins (RBP-eCLIP™), RNA modifications such as m6A (m6A-eCLIP™), alternative transcription start site and polyadenylation site usage (EndSeq™), and microRNA-mRNA interactions (miR-eCLIP™), profile translation (eRibo™) and probe RNA structure (eSHAPE).
About Eclipsebio
Eclipsebio is a private biotechnology company developing first-in-class technologies to enable faster and more effective development of RNA therapeutics. The company offers its end-to-end RNA genomics products as services and kits and also provides custom RNA genomics services for select partners. Eclipsebio is headquartered in San Diego. For more info, visit www.eclipsebio.com.
Contacts
Company Contact: Peter Chu, Ph.D., CEO, info@eclipsebio.com, +1.858.255.8115
Media Contact: Jessica Yingling, Ph.D., Little Dog Communications Inc., jessica@litldog.com, +1.858.344.8091
